NCT02041715View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802

PHASE1TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Ebola Virus Infection
Interventions
DRUG

TKM-100802 for Injection

IV infusion

DRUG

Placebo

IV infusion

Trial Locations (1)

78209

Healthcare Discoveries, LLC d/b/a ICON Development Solutions, San Antonio

Sponsors
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Arbutus Biopharma Corporation

INDUSTRY

NCT02041715 - Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802 | Biotech Hunter | Biotech Hunter